ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Jane Street Group LLC

Jane Street Group LLC lowered its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 23.9% in the third quarter, Holdings Channel reports. The firm owned 19,976 shares of the specialty pharmaceutical company’s stock after selling 6,287 shares during the period. Jane Street Group LLC’s holdings in ANI Pharmaceuticals were worth $1,192,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of ANIP. State Street Corp boosted its stake in ANI Pharmaceuticals by 9.1% during the 3rd quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock worth $41,991,000 after purchasing an additional 58,698 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of ANI Pharmaceuticals by 3.5% in the second quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company’s stock worth $40,132,000 after buying an additional 21,053 shares in the last quarter. Pacer Advisors Inc. boosted its position in ANI Pharmaceuticals by 23,259.8% during the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock worth $33,907,000 after acquiring an additional 565,910 shares during the last quarter. Global Alpha Capital Management Ltd. grew its stake in ANI Pharmaceuticals by 1.8% during the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock valued at $32,005,000 after acquiring an additional 9,500 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in ANI Pharmaceuticals by 3.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 250,346 shares of the specialty pharmaceutical company’s stock valued at $14,936,000 after acquiring an additional 8,869 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at $2,943,540. The trade was a 2.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Nikhil Lalwani sold 33,481 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the sale, the chief executive officer now directly owns 370,378 shares in the company, valued at $21,478,220.22. This represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,231 shares of company stock worth $2,434,286. 12.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ANIP has been the topic of a number of research reports. Raymond James raised their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. HC Wainwright reissued a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. StockNews.com cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Piper Sandler started coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target on the stock. Finally, Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $77.71.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $54.41 on Monday. The firm has a market cap of $1.14 billion, a PE ratio of -98.93 and a beta of 0.73. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $70.81. The business’s fifty day simple moving average is $57.36 and its 200-day simple moving average is $59.56.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. The firm had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals’s revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.05 EPS. Equities analysts forecast that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.